BioLife Solutions (BLFS) news
Recent news
Biolife Solutions Q2 EPS USD 0.91
AInvest Wire · Aug 6, 2026Biolife Solutions Q2 revenue USD 28.466 million vs. IBES estimate USD 27.7 million
BioLife Solutions, Inc. (Nasdaq: BLFS) reported second-quarter revenue of $28.466 million, exceeding the IBES estimate of $27.7 million. This performance reflects the company’s ongoing efforts to streamline its business operations and focus on higher-margin product lines. In a strategic move,…
AInvest Wire · Aug 6, 2026Biolife Solutions Inc: H.C. Wainwright cuts to neutral from buy; cuts target price to $31 from $32
H.C. Wainwright & Co. has revised its stance on Biolife Solutions Inc (NASDAQ: BLFS), downgrading the stock from "Buy" to "Neutral" and reducing its price target to $31 from $32. The adjustment reflects a reassessment of the company's near-term outlook and market dynamics. The firm noted that while…
AInvest Wire · Jul 23, 2026Biolife Solutions Inc: TD Cowen cuts to hold from buy; cuts target price to $31 from $33
AInvest Wire · Jul 23, 2026Biolife Solutions: co may be required to pay Repligen termination fee of $59 mln, if deal terminates under certain circumstances - SEC filing
Repligen Corporation (NASDAQ: RGEN) and BioLife Solutions, Inc. (NASDAQ: BLFS) have entered into a definitive agreement for Repligen to acquire BioLife for a total enterprise value of approximately $1.5 billion, with 64% in Repligen common stock . According to a recent SEC filing, BioLife may be…
AInvest Wire · Jul 22, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.